CKMT1 and NCOA1 expression as a predictor of clinical outcome in patients with advanced-stage head and neck squamous cell carcinoma
Por:
Pavon, MA, Parreno, M, Tellez-Gabriel, M, Leon, X, Arroyo-Solera, I, Lopez, M, Cespedes, MV, Casanova, I, Gallardo, A, Lopez-Pousa, A, Mangues, MA, Quer, M, Barnadas, A, Mangues, R
Publicada:
1 abr 2016
Resumen:
Background. We studied the association between the expression of a subset of previously identified genes and clinical outcome in patients with head and neck cancer.
Methods. We analyzed by reverse transcriptase-polymerase chain reaction (RT-PCR) the expression of 89 genes in tumor biopsies from stage III to IVa/b chemotherapy treated patients (n=46). Two additional cohorts analyzed by RNAseq (The Cancer Genome Atlas [TCGA] project; n=371) or immunohistochemistry (IHC; n=73) were used to validate results.
Results. Thirty genes were associated with local-recurrence or progression-free survival. The best multi-gene decision-tree model to predict local recurrence included nuclear receptor coactivator 1 (NCOA1) and serum-amyloid A2 (SAA2) expression, whereas the best model to predict disease recurrence included creatine kinase mitochondrial 1 (CKMT1) and metal-regulatory transcription factor 1 (MTF1). Both models were associated with cancer-specific survival. Results were confirmed analyzing the RNAseq data included in the TCGA project. CKMT1 and NCOA1 were identified as independent risk factors for survival in an independent cohort analyzed by immunohistochemistry.
Conclusion. CKMT1 and NCOA1 expression has prognostic significance in advanced-stage head and neck carcinoma. (C) 2015 Wiley Periodicals, Inc.
Filiaciones:
Pavon, MA:
HSCSP, IIB Sant Pau, GOA, Barcelona, Spain
Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid, Spain
Parreno, M:
HSCSP, IIB Sant Pau, Translat Mol Oncol, Barcelona, Spain
Tellez-Gabriel, M:
HSCSP, IIB Sant Pau, GOA, Barcelona, Spain
Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid, Spain
Leon, X:
Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid, Spain
HSCSP, IIB Sant Pau, Dept Otorhinolaryngol, Barcelona, Spain
Arroyo-Solera, I:
HSCSP, IIB Sant Pau, GOA, Barcelona, Spain
Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid, Spain
Lopez, M:
HSCSP, IIB Sant Pau, Dept Otorhinolaryngol, Barcelona, Spain
Cespedes, MV:
HSCSP, IIB Sant Pau, GOA, Barcelona, Spain
Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid, Spain
Casanova, I:
HSCSP, IIB Sant Pau, GOA, Barcelona, Spain
Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid, Spain
Gallardo, A:
Clin Girona, Dept Pathol, Girona, Spain
Lopez-Pousa, A:
Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid, Spain
HSCSP, IIB Sant Pau, Dept Med Oncol, Barcelona, Spain
Mangues, MA:
HSCSP, IIB Sant Pau, Dept Pharm, Barcelona, Spain
Quer, M:
HSCSP, IIB Sant Pau, Dept Otorhinolaryngol, Barcelona, Spain
Barnadas, A:
HSCSP, IIB Sant Pau, Dept Med Oncol, Barcelona, Spain
Mangues, R:
HSCSP, IIB Sant Pau, GOA, Barcelona, Spain
Ctr Invest Biomed Red Bioingn Biomat & Nanomed CI, Madrid, Spain
|